ATE389439T1 - Behandlung von einschlusskörper-myositis - Google Patents

Behandlung von einschlusskörper-myositis

Info

Publication number
ATE389439T1
ATE389439T1 AT05008993T AT05008993T ATE389439T1 AT E389439 T1 ATE389439 T1 AT E389439T1 AT 05008993 T AT05008993 T AT 05008993T AT 05008993 T AT05008993 T AT 05008993T AT E389439 T1 ATE389439 T1 AT E389439T1
Authority
AT
Austria
Prior art keywords
inclusion body
body myositis
treatment
ibm
myositis
Prior art date
Application number
AT05008993T
Other languages
English (en)
Inventor
Lars Olbe
Thord Rosen
Original Assignee
Sahltech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sahltech Ab filed Critical Sahltech Ab
Application granted granted Critical
Publication of ATE389439T1 publication Critical patent/ATE389439T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crushing And Grinding (AREA)
  • Glass Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05008993T 2005-04-25 2005-04-25 Behandlung von einschlusskörper-myositis ATE389439T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05008993A EP1716887B1 (de) 2005-04-25 2005-04-25 Behandlung von Einschlusskörper-Myositis

Publications (1)

Publication Number Publication Date
ATE389439T1 true ATE389439T1 (de) 2008-04-15

Family

ID=34935670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05008993T ATE389439T1 (de) 2005-04-25 2005-04-25 Behandlung von einschlusskörper-myositis

Country Status (5)

Country Link
US (1) US20080221019A1 (de)
EP (1) EP1716887B1 (de)
AT (1) ATE389439T1 (de)
DE (1) DE602005005454T2 (de)
WO (1) WO2006115448A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9778250B2 (en) 2011-05-10 2017-10-03 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
EP2729810B1 (de) 2011-07-07 2018-10-10 Stichting Katholieke Universiteit Myositis
WO2015023626A1 (en) * 2013-08-13 2015-02-19 The Brigham And Women's Hospital, Inc. Sensitive diagnostic assay for inclusion body myositis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
WO2002102412A2 (en) * 2001-06-18 2002-12-27 Mcgill University Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
US20040259784A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
EP1716887A1 (de) 2006-11-02
US20080221019A1 (en) 2008-09-11
EP1716887B1 (de) 2008-03-19
DE602005005454T2 (de) 2009-04-30
DE602005005454D1 (de) 2008-04-30
WO2006115448A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EA200900392A1 (ru) Комбинированное лечение сахарного диабета
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
ATE505201T1 (de) Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
NO20090202L (no) Prolylhydroksylaseinhibitorer
TW200745037A (en) Organic compounds
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
NO20073765L (no) Forbindelser for behandling av flaviviridae
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
NO20076405L (no) Anvendelse av 24-nor-UDCA
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
PL1973539T3 (pl) Zastosowanie pochodnych heterocyklicznych sulfamidów sprzężonych z benzenem do leczenia depresji
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
DE602005005454D1 (de) Behandlung von Einschlusskörper-Myositis
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties